Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elasomeran (Moderna Inc)
- Development stage
- Approved
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Elasomeran (Spikevax, mRNA-1273) is a lipid nanoparticle-encapsulated mRNA vaccine developed by Moderna for the prevention of COVID-19. It encodes the prefusion-stabilized spike (S) protein of the SARS-CoV-2 virus. Upon intramuscular injection, the mRNA is taken up by host cells and translated into the spike protein, which then triggers an adaptive immune response, including the production of neutralizing antibodies and T-cell activation. It was one of the first mRNA vaccines to receive emergency use authorization and subsequent full approval globally.
- Brand names
- Spikevax
- Other names
- Moderna COVID-19 VaccineModerna
02
Targets
Spike-TCR (T-cell receptor recognizing SARS-CoV-2 spike-derived peptides on MHC class I)SARS-CoV-2 spike protein-specific T-cell receptor (MHC class II restricted)BCR (B-cell receptor)ACE2 (Angiotensin-converting enzyme 2)PRR (Pattern recognition receptors)Host ribosomal translational machinery
Beyond the preview
Go deeper on elasomeran (Moderna Inc).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elasomeran (Moderna Inc).